Axsome Therapeutics Secures Long-Term Patent Exclusivity for SUNOSI Through Settlement
Summary
Axsome Therapeutics announced a settlement agreement resolving patent litigation for its product SUNOSI, securing market exclusivity until at least March 2040.
Key Events
-
Patent Litigation Resolved
Axsome Therapeutics has settled patent litigation with Alkem Laboratories Ltd. regarding its product SUNOSI (solriamfetol).
-
Extended Market Exclusivity Secured
The settlement grants Alkem a license to sell a generic version of SUNOSI starting on or after September 1, 2040 (with pediatric exclusivity) or March 1, 2040 (without), significantly extending Axsome's exclusivity.
-
Remaining Litigation
Similar patent litigation brought by Axsome against another party related to SUNOSI remains pending.
Analysis
Axsome Therapeutics has reached a settlement agreement with Alkem Laboratories Ltd., resolving patent litigation concerning its product SUNOSI (solriamfetol). This agreement grants Alkem a license to sell a generic version of SUNOSI starting on or after September 1, 2040, if pediatric exclusivity is granted, or March 1, 2040, if not. This significantly extends the market exclusivity for SUNOSI, providing long-term clarity and protection for a key revenue-generating product. While similar patent litigation against another party remains pending, this resolution removes a significant legal overhang and strengthens Axsome's intellectual property position for SUNOSI for nearly two decades.
At the time of this filing, AXSM was trading at $181.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.1B. The 52-week trading range was $86.99 to $191.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.